Update in Women's Health
Authors: Carolyn Crandall, Janet P. Pregler
Journal: Annals of Internal Medicine (2005)

Updates6 December 2005Update in Women's HealthCarolyn Crandall, MD, MS and Janet P. Pregler, MDCarolyn Crandall, MD, MSFrom the Iris Cantor-UCLA Women's Health Center, David Geffen School of Medicine at the University of California at Los Angeles, Los Angeles, California.Search for more papers by this author and Janet P. Pregler, MDFrom the Iris Cantor-UCLA Women's Health Center, David Geffen School of Medicine at the University of California at Los Angeles, Los Angeles, California.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-143-11-200512060-00011 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail This Update in Women's Health reviews the past year's research publications that have the most relevance to the practice of internal medicine. We have included a summary of new guideline recommendations for the prevention of heart disease in women. Our selection process was guided by advice from our colleagues in general internal medicine, geriatrics, obstetrics and gynecology, cardiology, and oncology.Breast CancerMagnetic Resonance Imaging Was More Sensitive than Ultrasound, Mammography, or Clinical Breast Examination for Detecting Breast Cancer in BRCA1 and BRCA2 Mutation Carriers Warner E, Plewes DB, Hill KA, et al. Surveillance of BRCA1 and BRCA2 mutation carriers ...References1. Elmore JG, Armstrong K, Lehman CD, Fletcher SW. Screening for breast cancer. JAMA. 2005;293:1245-56. [PMID: 15755947] CrossrefMedlineGoogle Scholar2. Smith RA, Cokkinides V, Eyre HJ. American Cancer Society Guidelines for the Early Detection of Cancer, 2005. CA Cancer J Clin. 2005;55:31-44; quiz 55-6. [PMID: 15661685] CrossrefMedlineGoogle Scholar3. Robson ME, Offit K. Breast MRI for women with hereditary cancer risk [Editorial]. JAMA. 2004;292:1368-70. [PMID: 15367560] CrossrefMedlineGoogle Scholar4. Liberman L. Breast cancer screening with MRI—what are the data for patients at high risk? [Editorial]. N Engl J Med. 2004;351:497-500. [PMID: 15282358] CrossrefMedlineGoogle Scholar5. U.S. Preventive Services Task Force. Screening for breast cancer: recommendations and rationale. Ann Intern Med. 2002;137:344-6. [PMID: 12204019] LinkGoogle Scholar6. Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol. 2005;23:619-29. [PMID: 15545664] CrossrefMedlineGoogle Scholar7. Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet. 2005;366:455-62. [PMID: 16084253] CrossrefMedlineGoogle Scholar8. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003;349:1793-802. [PMID: 14551341] CrossrefMedlineGoogle Scholar9. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002;359:2131-9. [PMID: 12090977] CrossrefMedlineGoogle Scholar10. Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol. 2003;21:4042-57. [PMID: 12963702] CrossrefMedlineGoogle Scholar11. American College of Obstetricians and Gynecologists. Routine cancer screening: Committee Opinion No. 128. Washington, DC: American College of Obstetricians and Gynecologists; 1993. Google Scholar12. American College of Physicians. Screening for ovarian cancer: recommendations and rationale. Ann Intern Med. 1994;121:141-2. [PMID: 8017728] LinkGoogle Scholar13. U.S. Preventive Services Task Force. Guide to Clinical Preventive Services, 2nd and 3rd eds. McLean, Virginia: International Medical Publishing; 2002. Google Scholar14. Goff BA, Mandel L, Muntz HG, Melancon CH. Ovarian carcinoma diagnosis. Cancer. 2000;89:2068-75. [PMID: 11066047] CrossrefMedlineGoogle Scholar15. Du Bois A, Rochon J, Lamparter C, Pfisterer J. Pattern of care and impact of participation in clinical studies on the outcome in ovarian cancer. Int J Gynecol Cancer. 2005;15:183-91. [PMID: 15823098] CrossrefMedlineGoogle Scholar16. Olson SH, Mignone L, Nakraseive C, Caputo TA, Barakat RR, Harlap S. Symptoms of ovarian cancer. Obstet Gynecol. 2001;98:212-7. [PMID: 11506835] CrossrefMedlineGoogle Scholar17. Eltabbakh GH, Yadav PR, Morgan A, Yadev PR. Clinical picture of women with early stage ovarian cancer. Gynecol Oncol. 1999;75:476-9. [PMID: 10600311] CrossrefMedlineGoogle Scholar18. Vine MF, Ness RB, Calingaert B, Schildkraut JM, Berchuck A. Types and duration of symptoms prior to diagnosis of invasive or borderline ovarian tumor. Gynecol Oncol. 2001;83:466-71. [PMID: 11733956] CrossrefMedlineGoogle Scholar19. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin: clinical management guidelines for obstetrician-gynecologists. Number 45, August 2003. Cervical cytology screening (replaces committee opinion 152, March 1995). Obstet Gynecol. 2003;102:417-27. [PMID: 12907124] MedlineGoogle Scholar20. Walsh JM, Pignone M. Drug treatment of hyperlipidemia in women. JAMA. 2004;291:2243-52. [PMID: 15138247] CrossrefMedlineGoogle Scholar21. Daviglus ML, Stamler J, Pirzada A, Yan LL, Garside DB, Liu K, et al. Favorable cardiovascular risk profile in young women and long-term risk of cardiovascular and all-cause mortality. JAMA. 2004;292:1588-92. [PMID: 15467061] CrossrefMedlineGoogle Scholar22. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized, controlled trial. JAMA. 2002;288:321-33. [PMID: 12117397] CrossrefMedlineGoogle Scholar23. Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized, controlled trial. JAMA. 2003;289:2651-62. [PMID: 12771112] CrossrefMedlineGoogle Scholar24. FDA approves new labels for estrogen and estrogen plus progestin therapies for postmenopausal women following review of Women's Health Initiative data. Rockville, MD: Food and Drug Administration; 8 January 2003. Google Scholar25. Executive summary. Hormone therapy. Obstet Gynecol. 2004;104:1S-4S. [PMID: 15458927] CrossrefMedlineGoogle Scholar26. Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, Lane DS, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA. 2004;291:2947-58. [PMID: 15213206] CrossrefMedlineGoogle Scholar27. Gruber CJ, Tschugguel W, Schneeberger C, Huber JC. Production and actions of estrogens. N Engl J Med. 2002;346:340-52. [PMID: 11821512] CrossrefMedlineGoogle Scholar28. Kronenberg F, Fugh-Berman A. Complementary and alternative medicine for menopausal symptoms: a review of randomized, controlled trials. Ann Intern Med. 2002;137:805-13. [PMID: 12435217] LinkGoogle Scholar29. Workowski KA, Levine WC, Wasserheit JN. U.S. Centers for Disease Control and Prevention guidelines for the treatment of sexually transmitted diseases: an opportunity to unify clinical and public health practice. Ann Intern Med. 2002;137:255-62. [PMID: 12186516] LinkGoogle Scholar Author, Article, and Disclosure InformationAuthors: Carolyn Crandall, MD, MS; Janet P. Pregler, MDAffiliations: From the Iris Cantor-UCLA Women's Health Center, David Geffen School of Medicine at the University of California at Los Angeles, Los Angeles, California.Acknowledgments: The authors thank their colleagues at the David Geffen School of Medicine for their assistance in preparing this article.Disclosures: None disclosed.Corresponding Author: Janet P. Pregler, MD, Iris Cantor-UCLA Women's Health Center, David Geffen School of Medicine at UCLA, 100 UCLA Medical Plaza, Suite 250, Los Angeles, CA 90077; e-mail, [email protected]ucla.edu.Current Author Addresses: Drs. Crandall and Pregler: Iris Cantor-UCLA Women's Health Center, David Geffen School of Medicine at UCLA, 100 UCLA Medical Plaza, Suite 250, Los Angeles, CA 90077. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 6 December 2005Volume 143, Issue 11Page: 823-829KeywordsBone densityBreast cancerCandidiasisCardiovascular therapyEstrogensHysterectomyMammographyObstetrics and gynecologyOvarian cancerUltrasound imaging ePublished: 6 December 2005 Issue Published: 6 December 2005 Copyright & PermissionsCopyright © 2005 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...